ORION CORPORATION PRESS RELEASE 2 JUNE 2017 at 11.06 a.m. EEST
Orion Diagnostica's co-operation negotiations in Oulu completed
The co-operation negotiations which were initiated in April in Orion Diagnostica Oy, a subsidiary of Orion Corporation focusing on diagnostic tests, have been completed.
As a result, a decision has been made to terminate the operations of Orion Diagnostica Oy in Oulu and move the operations entirely to Espoo. The negotiations concerned 14 employees, who will primarily be offered a transfer to Orion Diagnostica's location in Espoo.
Orion Diagnostica Oy received a notice of termination from its landlord in April to terminate the lease agreement of Orion Diagnostica's premises in Oulu. For this reason, the operations of Orion Diagnostica Oy in the current premises will end by the end of September 2017 at the latest. Orion Diagnostica Oy gave a negotiation proposal, as laid down in the Finnish Act on Co-operation within Undertakings, in April on reorganising operations and possible personnel reductions in Oulu. The negotiations concerned 14 employees.
Kaisa Tarkkanen, President, Orion Diagnostica Oy
tel. +358 10 426 3268
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.